Today: 29 April 2026
UEC stock jumps nearly 11% as uranium supply squeeze talk returns — and a Feb. 27 vote looms
14 January 2026
2 mins read

UEC stock jumps nearly 11% as uranium supply squeeze talk returns — and a Feb. 27 vote looms

New York, January 14, 2026, 14:02 EST — Regular session underway

  • Shares of Uranium Energy Corp climbed roughly 10.8% in afternoon trading, beating the wider gains seen across the uranium sector.
  • Traders are turning their attention back to the sector amid signs of a tightening U.S. uranium market.
  • Anfield Energy revealed that a unit of Uranium Energy purchased $4 million worth of subscription receipts, with shareholder approval anticipated near Feb. 27.

Shares of Uranium Energy Corp climbed 10.8% to $17.23 on Wednesday, after peaking at $17.34 earlier. The stock started the day at $15.55 and dipped to a low of $15.13, with roughly 9.4 million shares traded.

This move counts now because uranium prices barely have to shift to rattle this trade. The spot market remains thin, the supply chain is tangled in politics, and utilities continue locking in fuel through multi-year contracts.

A Reuters analysis on Wednesday highlighted a growing U.S. supply gap as consumption outpaces mine production, driven by demand from power-hungry data centers and new reactor projects. U.S. uranium spot prices are expected to finish 2025 near $82 a pound, with executives involved in contract negotiations eyeing long-term prices closer to $100, the report noted. U.S. mine output this year is projected at about 1 million pounds, while annual consumption tops 50 million pounds.

The uranium sector showed strength. Global X Uranium ETF climbed roughly 3%. Cameco advanced about 1.9%, Energy Fuels jumped around 5.5%, and Denison Mines increased close to 4.6%. Uranium Royalty posted a slight gain.

Anfield Energy announced Tuesday it secured $10 million in financing, including a $4 million subscription receipt purchase by UEC Energy Corp, a fully owned subsidiary of Uranium Energy. The company plans a special shareholder meeting “on or about” Feb. 27 to approve Uranium Energy as a “Control Person.” The subscription receipts will convert into shares once escrow conditions are satisfied, with a cutoff date of March 31. GlobeNewswire

Subscription receipts are a typical Canadian financing method: cash is held in escrow and only turns into shares once all approvals are secured. For Anfield, this means getting the green light from the TSX Venture Exchange and a vote by disinterested shareholders.

Analysts are turning bullish on the group once more. Bank of America’s Lawson Winder told Business Insider he anticipates “a sharp H2’26E price recovery for uranium,” though his forecast centers on Cameco rather than the smaller U.S.-listed miners. Business Insider

On Uranium Energy’s investor page, a TradeTech indicator listed uranium at roughly $83.25 per pound on Wednesday, matching spot prices mentioned in recent market reports.

The downside, however, is straightforward. Uranium prices tend to drop fast when risk appetite wanes, and mining plus processing timelines don’t bend to a trader’s timetable. Any hiccup in approvals related to Anfield’s vote or escrow terms would put the “strategic stake” story under pressure.

The next clear catalyst is the Feb. 27 Anfield meeting, followed by the March 31 escrow deadline. Traders remain focused on whether long-term uranium contracts can actually push past the $100-per-pound mark, a threshold many see as critical.

Stock Market Today

  • Humana Stock Dips Over 2% Amid Profit Forecast Revision
    April 29, 2026, 9:26 AM EDT. Humana Inc. (HUM) stock dropped more than 2% premarket after the health insurer maintained its adjusted full-year profit forecast at $9 per share but lowered its nonadjusted earnings estimate to at least $8.36 from $8.89. The company reported a 23% rise in first-quarter revenue and adjusted earnings per share beating expectations. However, charges from a multiyear transformation program to realign costs and operations weighed on results. Rising medical and pharmaceutical expenses, coupled with tighter government rules on Medicare Advantage payments, have pressured the sector. Humana, a major Medicare Advantage provider, faces ongoing margin challenges. Year to date, Humana shares have fallen about 13% amid these industry headwinds.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Verizon stock up despite fresh network outage — what Wall Street watches into earnings
Previous Story

Verizon stock up despite fresh network outage — what Wall Street watches into earnings

BMNR stock rises as BitMine pushes last-minute vote on plan to lift share cap to 50 billion
Next Story

BMNR stock rises as BitMine pushes last-minute vote on plan to lift share cap to 50 billion

Go toTop